Efficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics

Experimental Hematology

Volumn 36, Issue 1, 2008, Pages 9-16

  Yankelevich, Maxim ^a   Goodell, Margaret A ^a   Kaplan, Joseph ^b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL COMPOSITION; CELL KINETICS; CELL LINE; CELL MATURATION; CHEMOTHERAPY; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; FEMALE; GRANULOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; THERAPY DELAY;

ANIMALS; ANTIGENS, CD34; BONE MARROW CELLS; CELL DIVISION; COLONY-FORMING UNITS ASSAY; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION, PRECLINICAL; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTES; HEMATOPOIETIC STEM CELL MOBILIZATION; LEUKOCYTE COUNT; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOPOIESIS; NEUTROPENIA; PLATELET COUNT; RECEPTORS, CHEMOKINE; SPECIFIC PATHOGEN-FREE ORGANISMS;

MURINAE;

EID: 37249019648     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.08.019     Document Type: Article

References (19)

1. Rahiala J., Perkkio M., and Riikonen P. Prospective and randomized comparison of early versus delayed prophylactic administration of granulocyte colony-stimulating factor (Filgrastim) in children with cancer. Med Pediatr Oncol 32 (1999) 326-330
2. Elonen E., Jantunen E., Koistinen P., et al. G-CSF (lenograstim) following chemotherapy in the induction treatment of acute lymphoblastic leukemia (ALL) in adults. A randomized study between early and delayed start. Blood 88 Suppl 1 (1996) 213a
3. Morrison S.J., Wright D.E., and Weissman I.L. Cyclophosphamide/granulocyte colony-stimulating factor induces hematopoietic stem cells to proliferate prior to mobilization. Proc Natl Acad Sci U S A 94 (1997) 1908-1913
4. Levesque J.P., Liu F., Simmons P.J., et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 104 (2004) 65-72
5. Fleming T.J., Fleming M.L., and Malek T.R. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol 151 (1993) 2399-2408
6. Hestdal K., Ruscetti F.W., Ihle J.N., et al. Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol 147 (1991) 22-28
7. Krause D.S., Takahiko I., Fackler M.J., et al. Characterization of murine CD34, a marker for hematopoietic progenitor and stem cells. Blood 84 (1994) 691-701
8. Okuno Y., Iwasaki H., Huettner C.S., et al. Differential regulation of the human and murine CD34 genes in hematopoietic stem cells. Proc Natl Acad Sci U S A 99 (2002) 6246-6251
9. Ebihara Y., Xu M.J., Manabe A., et al. Exclusive expression of G-CSF receptor on myeloid progenitors in bone marrow CD34+ cells. Br J Haematol 109 (2000) 153-161
10. Tassi C., Tazzari P.L., Bonifazi F., et al. Short- and long-term hematological surveillance of healthy donors of allogeneic peripheral hematopoietic progenitors mobilized with G-CSF: a single institution prospective study. Bone Marrow Transplant 36 (2005) 289-294
11. Timmer-Bonte J.N., de Mulder P.H., Peer P.G., et al. Timely withdrawal of G-CSF reduces the occurrence of thrombocytopenia during dose-dense chemotherapy. Breast Cancer Res Treat 93 (2005) 117-123
12. Petit I., Szyper-Kravitz M., Nagler A., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 3 (2002) 687-694
13. Stewart F.M., Temeles D., Lowry, Thraves T., Grosh W.W., and Quesenberry P.J. Post-5-fluorouracil human marrow: stem cell characteristics and renewal properties after autologous marrow transplantation. Blood 181 (1993) 2283-2289
14. Riccardi A., Danova M., Paccagnella A., et al. Bone marrow myeloid cell kinetics during treatment of small cell carcinoma of the lung with chemotherapy not associated and associated with GM-CSF. Ann Hematol 66 (1993) 185-193
15. Ostby I., Kvalheim G., Rusten L.S., and Grottum P. Mathematical modeling of granulocyte reconstitution after high-dose chemotherapy with stem cell support: effect of post-transplant G-CSF treatment. J Theor Biol 231 (2004) 69-83
16. Dolgopolov I., Andreeva L., Yankelevich M., et al. Delayed Introduction of G-CSF after chemotherapy does not affect peripheral blood stem cell yield and engraftment kinetics in children with high-risk malignancies: retrospective study of 45 cases. Am J Hematol 73 (2003) 225-229
17. Gomez A.T., Jimenez M.A., Alvarez M.A., et al. Optimal timing of granulocyte colony-stimulating factor (G-CSF) administration after bone marrow transplantation: a prospective randomized study. Ann Hematol 71 (1995) 65-70
18. Hofmann W.K., Seipelt G., Langenhan S., et al. Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia. Ann Hematol 81 (2002) 570-574
19. Weiser M.A., O'Brien S., Thomas D.A., et al. Comparison of two different schedules of granulocyte colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristin, and dexamethasone) regimen. Cancer 94 (2002) 285-291